Join Evidation during the J.P
Sean Hashmi, MD, is the regional medical director of Lifestyle & Obesity Medicine for the Southern California Permanente Medical Group, and national chair of the interregional clinical practice group for Lifestyle & Obesity Medicine, The Permanente Federation.
Microb Pathog (2022) 165:105216
Here is a general timeline based on clinical experience: Week 1-2: Most patients notice improved energy levels and reduced fatigue
Weight loss goals and expectations : NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for weight management in adults with at least one weight-related comorbidity and a BMI of at least 35 kg/m (or at least 30 kg/m for people from certain ethnic backgrounds), as part of a specialist weight management service
Compared to continued use, they found that stopping or interrupting GLP-1 treatment for as little as six months was linked to a significant increase in the risk of major cardiovascular events